DNAnexus, founded in 2009, is a cloud-based platform for biomedical informatics and data management. DNAnexus strives to provide security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health with the goal of accelerating medical discovery. The company is headquartered in Mountain View, California.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/08/2022 | Series I | $200MM | $xx.xx | $61.63B | Blackstone Growth, Foresite Capital, Gv, Innovatus Capital Partners, Northpond Ventures, Perceptive Advisors | |
Price per Share
$xx.xx
Shares Outstanding
327,976,382
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Blackstone Growth, Foresite Capital, Gv, Innovatus Capital Partners, Northpond Ventures, Perceptive Advisors
|
||||||
06/09/2020 | Series G | $15.51MM | $xx.xx | $22.64B | First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital | |
Price per Share
$xx.xx
Shares Outstanding
42,529,695
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
|
||||||
06/09/2020 | Series H | $47.15MM | $xx.xx | $22.64B | First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital | |
Price per Share
$xx.xx
Shares Outstanding
127,432,428
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, Foresite Capital, Gv, Northpond Ventures, Perceptive Advisors, Regeneron Pharmaceuticals, Tpg Capital
|
||||||
02/06/2019 | Series F-2 | $14.43MM | $xx.xx | $13.59B | Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode | |
Price per Share
$xx.xx
Shares Outstanding
40,909,900
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
|
||||||
02/06/2019 | Series F-1 | $30.78MM | $xx.xx | $13.59B | Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode | |
Price per Share
$xx.xx
Shares Outstanding
91,623,776
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Foresite Capital, Gv, Innovatus Capital Partners, Tpg Biotech, Wuxi Nextcode
|
||||||
01/02/2018 | Series E | $22.74MM | $xx.xx | $7.51B | Claremont Creek Ventures, Existing Investors, Foresite Capital, Gv, Microsoft, Midcap Financial, Tpg Biotech, Wuxi Nextcode | |
Price per Share
$xx.xx
Shares Outstanding
67,694,865
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, Existing Investors, Foresite Capital, Gv, Microsoft, Midcap Financial, Tpg Biotech, Wuxi Nextcode
|
||||||
04/22/2015 | Series D | $15MM | $xx.xx | $8.39B | Wuxi Pharmatech | |
Price per Share
$xx.xx
Shares Outstanding
24,402,544
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Wuxi Pharmatech
|
||||||
01/03/2014 | Series C | $18.3MM | $xx.xx | $3.54B | Claremont Creek Ventures, First Round Capita, Gv, Tpg Biotech | |
Price per Share
$xx.xx
Shares Outstanding
55,454,543
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Claremont Creek Ventures, First Round Capita, Gv, Tpg Biotech
|
||||||
10/12/2011 | Series B | $15.3MM | $xx.xx | $3.28B | Felicis Ventures, First Round Capital, Gv, K9 Ventures, Softtech Vc, Tpg Biotech | |
Price per Share
$xx.xx
Shares Outstanding
7,559,292
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
4.1x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Felicis Ventures, First Round Capital, Gv, K9 Ventures, Softtech Vc, Tpg Biotech
|
||||||
08/03/2009 | Series A | $1.55MM | $xx.xx | $442.86MM | First Round Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,347,823
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
2.8x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital
|